Business
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value Potential for Ketamir-2 MIAMI, FL / ACCESS Newswire / May 27, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (\"MIRA\" or the \"Company\"), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric, inflammatory, and metabolic disorders, today announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement with MIRALOGX LLC, expanding the Company's licensed territory from the United States, Canada, and Mexico to worldwide rights across all countries in which patent rights exist.The amended agreement incorporates an expanded international patent portfolio now covering filings in the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea, representing the world's largest pharmaceutical markets.Ketamir-2 is MIRA's proprietary oral NMDA receptor modulator currently advancing toward planned Phase 2a development in chemotherapy-induced peripheral neuropathy (\"CIPN\"), an indication with significant unmet medical need. The Company recently announced positive Phase 1 clinical results across 56 healthy volunteers, demonstrating favorable safety, tolerability, and pharmacokinetic findings, with no serious adverse events or study discontinuations reported.Management CommentaryErez Aminov, Chairman and CEO of MIRA, stated: \"Securing worldwide rights for Ketamir-2 represents an important strategic milestone for MIRA and significantly strengthens the long-term global commercial potential of the program. As we advance toward planned Phase 2a development in CIPN, this expanded intellectual property position strengthens our ability to pursue global licensing, co-development or commercialization discussions with potential strategic partners.The amendment does not materially modify the previously disclosed core economic terms of the original license agreement.With worldwide IP rights secured and a completed Phase 1 data package in hand, MIRA is advancing Phase 2a protocol documentation for submission to the FDA under its active Investigational New Drug (IND) application.About Ketamir-2Ketamir-2 is a proprietary, orally bioavailable investigational new molecular entity designed to selectively modulate the NMDA recept...